ArticleDrug delivery and translational research2026
Enhanced subcutaneous delivery of antibody-drug conjugates with recombinant human hyaluronidase PH20: pharmacokinetics and tolerability in minipigs.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Subcutaneous (SC) administration of therapeutic antibodies offers advantages over intravenous (IV) delivery, including improved patient convenience and a pharmacokinetic (PK) profile characterized by lower peak plasma concentrations without affecting overall exposure. These benefits may extend to antibody-drug conjugates (ADCs), but development has been limited by concerns that cytotoxic payloads could persist at the SC injection site, causing local tissue toxicity. This study evaluated the local tolerability and PK of SC administration of two marketed ADCs containing camptothecin payloads-sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-Dxd)-in miniature pigs, with and without recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that facilitates rapid dispersion and absorption. Across injection volumes of 1-20 mL, rHuPH20 improved injection performance, reduced swelling and back-leakage and resulted in an absence of adverse histologic changes. SC delivery with rHuPH20 increased systemic exposure (AUC) of total ADC and payload by 33-54% compared to SC without rHuPH20, reaching 52-80% of the IV AUC while maintaining substantially lower C
Indexed as
Identifiers
42171942What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.